The ExoLuminate study is looking for people aged 18 and older who are at high risk for pancreatic cancer or have symptoms that suggest it. This study is testing a new blood test called ExoVerita™ that aims to find pancreatic cancer (pancreatic ductal adenocarcinoma or PDAC) earlier. The ExoVerita™ test works by isolating tiny particles called extracellular vesicles (EVs) from your blood and looking for specific protein markers. The goal is to see if this new test can detect pancreatic cancer as well as or better than current methods. The study is currently recruiting participants.

Study design

This is an observational study planning to enroll at least 1000 adults across the U.S. It is not specified if it is randomized or blinded.

What's involved

You would provide blood samples at specific times. The study will follow your data for two years after the initial three-year recruitment period.

Compensation

Not stated in the trial record.

Follow-up

Your data will be collected for up to two years after the initial three-year recruitment period, or until a diagnosis is made.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.